Vetcare's Veterinary Drug Development Becomes Its Own Company – Vetcare Innovations to Accelerate Growth
Vetcare Oy’s drug development operations are transitioning into a new company. The company's board has decided to spin off the development activities into an independent entity. Going forward, Vetcare Innovations will be responsible for all drug development projects within the group. The new company is wholly owned by Vetcare. As of June 1, 2025, Veli-Matti Riipinen has been appointed CEO of Vetcare Innovations.
The goal of the spin-off is to speed up the initiation of new development projects and increase transparency in both commercial operations and the financing of product development. At the same time, we want to strengthen our commitment to long-term development work.
“This new organizational structure supports our growth strategy and gives us better opportunities to accelerate both development and international expansion. Through Vetcare Innovations, we can build new partnerships and highlight our unique expertise in drug development.” – Olli Kuussaari, Group CEO
Vetcare’s Drug Development Has Three Clear Competitive Advantages
Vetcare conducts long-term development work with persistence and practicality, in collaboration with skilled partners. According to Veli-Matti Riipinen, the company has three distinct strengths that make Vetcare truly unique:
Innovation Isn’t Enough – We Make It Work in Practice
In addition to bold product development expertise, Vetcare group understands what the market truly needs and how to successfully launch innovative new medicines.
Responsible Development and Brave Choices
We seek potential where large pharma companies rarely operate. At our scale, this is both smart and responsible. We believe animals deserve better medicines, also for conditions that aren’t backed by blockbuster markets. That said, we don’t shy away from big challenges. We have excellent relationships with the industry’s largest players, and with their help, we can make even ambitious dreams come true.
Our Track Record Speaks for Itself
Vetcare has already developed two proprietary original drugs and secured marketing authorization for both. This is extremely rare in the industry.
“We’ve already done something very few others have. Even globally, it’s highly exceptional for a company to bring two original proprietary medicines to market back-to-back.” - Veli-Matti Riipinen, CEO, Vetcare Innovations
Commercial Partners Involved Early On
Vetcare Innovations aims to build a new kind of collaboration model with other pharmaceutical companies. The goal is to find development partners already before final clinical field trials. This allows for joint investment in product refinement, risk sharing, and faster commercialization.
What Happens Next?
Practical preparations are already underway. Provivo Oy, a company within the Vetcare Group, will form the basis of the new Vetcare Innovations. As CEO, Riipinen is responsible for building the new organization during 2025. The goal is for Vetcare Oy’s development specialists to transfer to Vetcare Innovations as employees at the beginning of 2026.
Read more about the marketing authorisations Vetcare has obtained for its original medicines:
Prevestrus vet, a dog estrus control medication, has received European marketing authorization